THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
109.21%
Total 13F principal
$222,446,567
Principal change
+$29,103,284
Total reported market value
$244,537,903
Number of holders
23
Value change
+$32,094,408
Number of buys
10
Number of sells
14

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q4 2021

As of 31 Dec 2021, THERAVANCE INC - CORPORATE OBLIG was held by 23 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $222,446,567 in principal (par value) of the bond. The largest 10 bondholders included LAZARD ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., WOLVERINE ASSET MANAGEMENT LLC, ADVENT CAPITAL MANAGEMENT /DE/, CSS LLC/IL, OAKTREE CAPITAL MANAGEMENT LP, DEUTSCHE BANK AG\, NEW YORK STATE COMMON RETIREMENT FUND, BANK OF AMERICA CORP /DE/, and PALISADE CAPITAL MANAGEMENT LLC/NJ. This page lists 23 institutional bondholders reporting positions for the Q4 2021 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.